Medley

Medley Current Liabilities

The Current Liabilities of Medley (4480.T) as of Nov 3, 2026 is 13.41 B JPY. In the previous year, Current Liabilities was 12.74 B JPY — a change of 5.26% (higher).

Current Liabilities

13.41 BJPY

YoY

5.26%

Last updated:

Current Liabilities of Medley is 2025 13.41 B JPY. Current Liabilities of Medley was 2024 12.74 B JPY. It decreases by 5.26% higher compared to the previous year.

The Medley Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
1.08 B JPY
Jan 1, 2019
2.02 B JPY
Jan 1, 2020
3.94 B JPY
Jan 1, 2021
4.22 B JPY
Jan 1, 2022
4.78 B JPY
Jan 1, 2023
5.81 B JPY
Jan 1, 2024
12.74 B JPY
Jan 1, 2025
13.41 B JPY
The Medley Current Liabilities history
YEARCurrent LiabilitiesYoY
13.41 BJPY+5.26%
12.74 BJPY+119.16%
5.81 BJPY+21.74%
4.78 BJPY+13.27%
4.22 BJPY+6.90%
3.94 BJPY+95.65%
2.02 BJPY+86.72%
1.08 BJPY+139.66%
450.40 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medley Stock analysis

What does Medley do? Medley Inc is a global company specializing in the production and sale of pharmaceutical products. The company was founded in 1985 as a small business and has since become a leading player in the pharmaceutical industry, operating in over 150 countries. Medley Inc produces a variety of products in different areas such as cardiology, gastroenterology, oncology, orthopedics, neurology, and dermatology. The company's business model is based on the development and sale of generic products, which are imitation products of patented drugs. Medley Inc focuses on producing high-quality and effective medicines at competitive prices. The company has production sites in various countries to meet the demand for drugs in each region. In addition to being a manufacturer of medicines, Medley Inc also offers services such as drug distribution, clinical studies, research and development, consulting for pharmaceutical manufacturers, and customer training. The company places great importance on the quality and safety of its products and services and has implemented a comprehensive quality management system to meet its high standards. The product range of Medley Inc includes a variety of drugs used in different indications, including well-known drugs such as Tamoxifen for cancer, Fluoxetine for depression, Oxycodone for pain relief, and Levofloxacin as an antibiotic. Medley Inc strives to make affordable medications accessible to all people and works to improve healthcare worldwide. The company has formed long-term partnerships with organizations and governments in emerging countries to enhance access to affordable medicines. Overall, Medley Inc is a significant player in the pharmaceutical industry, focusing on the production of generics and improving healthcare globally. Through its efforts in quality, innovation, and partnerships, the company aims to have a positive impact on society. Medley is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medley stock

Current Liabilities of Medley is 13.41 B JPY in 2025.

Current Liabilities of Medley changed from 12.74 B JPY to 13.41 B JPY, representing a 5.26% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Medley since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Medley historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Medley

All Key Metrics — Medley